Travere Therapeutics, Inc.
Ticker: 1438533
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q1 FY2026 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Q3 FY2023 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 127.20-22.8% | 164.86+44.0% | 114.45+40.0% | 81.73+29.9% | 62.90+16.2% | 54.12+30.8% | 41.37+11.5% | 37.10 |
| Total Income | 127.20-22.8% | 164.86+44.0% | 114.45+40.0% | 81.73+29.9% | 62.90+16.2% | 54.12+30.8% | 41.37+11.5% | 37.10 |
| EXPENSES | ||||||||
| Expenditure | 164.11+17.3% | 139.93+10.1% | 127.10+2.2% | 124.41+4.5% | 119.05-2.3% | 121.82-32.6% | 180.61+39.3% | 129.68 |
| Tax | -0.12-1300.0% | 0.01-50.0% | 0.02-50.0% | 0.04+150.0% | -0.08-188.9% | 0.09-52.6% | 0.19+1800.0% | 0.01 |
| PROFIT | ||||||||
| PBT | -36.72-242.8% | 25.71+301.8% | -12.74+69.1% | -41.19+24.9% | -54.84+21.2% | -69.57+48.8% | -135.77-52.2% | -89.23 |
| Net Profit | -37.10-244.3% | 25.71+301.5% | -12.76+69.1% | -41.23+24.8% | -54.81+22.2% | -70.41+48.3% | -136.06-190.3% | 150.74 |
| KEY METRICS | ||||||||
| OPM % | -29.02%-44.14pp | 15.12%+26.18pp | -11.05%+41.16pp | -52.21%+37.06pp | -89.27%+10.73pp | -100.00% | -100.00% | -100.00% |
| NPM % | -29.17%-44.76pp | 15.59%+26.74pp | -11.14%+39.30pp | -50.44%+36.70pp | -87.14%+12.86pp | -100.00% | -100.00%-200.00pp | 100.00% |
| EPS | -0.40-237.9% | 0.29+307.1% | -0.14+70.2% | -0.47+32.9% | -0.70+23.1% | -0.91+48.3% | -1.76-189.3% | 1.97 |
Corporate Events
Board MeetingTVTX
202612Jun
Board Meeting
Retirement of William Rote as Chief Research Officer and app…
SEC Filing ↗ Board MeetingTVTX
202619May
Board Meeting
The 2026 Annual Meeting of Stockholders was held to elect di…
SEC Filing ↗